Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you, operator, and welcome, everyone, to the Medivir webcast covering the second quarter of 2026. Looking back, this was the quarter where a lot of things came together for us. The phase 1b/2a data for Fostrox in combination with Lenvatinib was published in Clinical Cancer Research, which is one of oncology's most cited journals. We also took the important and exciting next step as the first patient was dosed in the randomized FLEX-HCC study in Korea, and we secured funding to take MIV-711 into a second rare bone indication, Legg-Calvé-Perthes disease, through an oversubscribed directed share issue of approximately 140 million SEK. I will take you through the clinical progress in both Fostrox and MIV-711, and Patrik Norgren will cover the financial details. With three funded phase two studies and a strengthened balance sheet, we are in the strongest position that we have been in in many years. So let me start with the three things we would like you to take away from the quarter. First, for Fostrox, in June, final safety and efficacy data from the phase 1b/2a study of Fostrox plus Lenvatinib were published in Clinical Cancer Research. A peer-reviewed confirmation that our liver-targeted mechanism delivers tumor-selective efficacy without impairing liver function, and a very important validation for when we speak with investigators, regulators, and potential partners. As I mentioned in May, the first patient was dosed in the FLEX-HCC, the randomized phase 2 study. We continue to see very strong engagement among the Korean investigators. Recruitment is progressing very well to enroll all patients within the 12-month period. Second, for MIV-711 and through the directed share issue. We are now taking MIV-711 into Legg-Calvé-Perthes disease, which is the second rare bone indication where we already have Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA. In parallel with that work, the study design for the proof-of-concept study in Osteogenesis Imperfecta has been finalized, and preparations are progressing very well; building two rare bone indications on the same established safety profile multiplies the value of the single drug candidate. Third, our financial position. The directed share issue of approximately 140 million SEK was oversubscribed and brought in new institutional investors, and we ended the quarter with 253 million SEK in cash. We now have funding in place for all three phase two studies. And. Let me stop there. Just to highlight our pipeline of first-in-class programs. The one change that you see on this slide from the previous quarter is the Perthes disease, where we are now. Then, we are in the planning phase of the phase 2 proof of concept study. We will not speak too much about it today, but Vetbiolix, our partner, is developing MIV-711. They continue to recruit patients, or dogs, into their study, with estimated readout in the fourth quarter of their ongoing randomized study. So that's an important value driver for us as well in the coming period. So, apart from myself, as I mentioned, our Chief Medical Officer, Pia Baumann, will go through the programs and our CFO will cover the financials, and Fredrik Öberg, our CSO, is here for our question and answer session as well. So with that, let me hand over to Pia Baumann, who will take you through the published phase 1b/2a data for Fostrox and the start of the FLEX-HCC study.
Thanks so much, Jens. Let me just first start with a reminder of why Fostrox is different. This is an oral prodrug that is activated in the liver, which means that we deliver the active substance, which is troxacitabine, where the tumor is and keeps systemic exposure low. I know we have said this before, but this is really important. And this is confirmed also by the biopsies from our study, where we can see DNA damage in the tumor tissue and no DNA damage in the surrounding healthy liver tissue. That really translates into what we see clinically. In combination with Lenvatinib, we see efficacy substantially beyond what has been reported in second-line HCC, including in the recently presented IMbrave251 study with atezolizumab and bevacizumab refractory patients. And we see a combination with our drug that is really well tolerated. The final data from our study were published, as just mentioned, in Clinical Cancer Research in June this year. Our strategic focus remains unchanged. There is still no approved treatment in second-line advanced liver cancer. That is a first-to-market opportunity in a market worth more than $2.5 billion annually. And I know that we are coming back a little bit to that in the summary from Jens. And this is why the FLEX-HCC study that is ongoing in Korea is now our highest clinical priority for the moment. So next slide. A few words on the publication itself, because it is an important milestone for this program. The full safety and efficacy data set from the phase 1b/2a study is now published in the peer-reviewed Journal of Clinical Cancer Research and Professor John J. Chong, who is also our primary investigator in the FLEX-HCC study, is the first author. The clinical message I would emphasize is the one that you can see in this title: tumor control without deterioration of liver function. In many other tumor types, it is the metastatic disease. I am sure you are all aware of this. It is the metastatic disease that drives mortality. In HCC, patients most often die from liver decompensation, and it is frequently caused by local tumor progression. So the treatment goal is to control the tumor in the liver without compromising the liver function. And that is a balance most systemic therapies struggle with. What you see in the figures here are the liver function parameters during the full treatment time. It is transaminase and the ALBI score where you measure liver function, and across the treatment cycles, all of these parameters remain stable over time. In other words, we achieve tumor control without deterioration of liver function. And that is what keeps patients fit enough not only to continue the treatment in this case, the study, but also to receive subsequent therapy. Next slide. I would also like to comment on the IMbrave251 study that was presented at ASCO this year. Because it is highly relevant for how we think about the second line. This study was large. It was over 550 patients asking whether it makes sense to continue immunotherapy after progression on an immunotherapy. Note that if you press one more time, you will see that. Note how favorable the patient population was. The patient had to receive at least four cycles of atezolizumab plus bevacizumab as prior treatment. And on that prior treatment, they needed to have documented disease control, meaning stable disease, partial response, or complete response on at least two tumor assessments. In other words, these patients who had done well on the first treatment are the patients who were included here. And even in that selected population, adding continued immunotherapy to a TKI yielded no benefit. In this case, Lenvatinib gave no benefit, neither in the overall survival nor in the progression-free survival, and the response rate remained below 8%. For us, the conclusion is clear: continuing immunotherapy is not the answer. After immunotherapy failure, the second line remains open and what is needed is a new mechanism of action. And that is precisely where Fostrox is positioned. You can go to the next slide. Against that background, let me mention our own efficacy data. In this context. It looks a little bit different than what we have shown before, but it is also intended to show, in the context of IMbrave251, that more than 75% of the patients treated with Fostrox plus Lenvatinib experienced tumor shrinkage, and the objective response rate was 24%. We had a time to progression. I know Jens already said that of 10.9 months and the median duration of response was more than seven months. And we actually see that the longest response is still ongoing beyond 36 months. And the part of this figure that might be interesting, again, in the context of IMbrave251, is the color coding on this figure. The orange bars are the patients who were primary refractory on their prior therapy. In other words, those who never responded to first-line treatment in this study also had tumor reduction. Patients benefited from Fostrox largely independent of how they responded in the previous line, which is not what we usually see in this setting. And it speaks to a generally different mechanism that is needed in the post-immunotherapy setting. This is the data set that gives us the confidence to run this randomized comparison. And that is the FLEX-HCC study. Go to the next slide. And this is the study design for this study. It is a study of 80 patients with advanced second-line hepatocellular carcinoma, all with one prior immunotherapy regimen. And they have a preserved liver function and good performance status. They are randomized 1 to 1 between Fostrox plus Lenvatinib or Lenvatinib alone. The primary endpoint for this study is objective response rate assessed by a blinded independent central review. We also look at duration of response. We also look at the duration of response. Progression-free survival. Overall survival. Safety. A secondary endpoint is also included, and tumor assessment is performed by CT or MRI every six weeks. The study is run with the Korean Cancer Study Group across 12 hospitals. As I mentioned before, Professor Chan is the principal investigator. The first patient in this study was dosed in May, and the enrollment is progressing well and very much in line with our plan to include all patients within 12 months. And we expect topline results from this study in the second half of 2027. There are two things that make this design attractive. We generate robust comparative data through an established research consortium, and the design allows for rapid readout. So, let me just move into MIV-711, our Cathepsin K inhibitor. As Jens said, we are now developing this drug or this molecule into two rare bone indications. Both these diseases are driven by excessive bone resorption. And in both, there is no approved drug treatment today. I will start with Perthes disease. So, Perthes disease or it is also called Legg-Calvé-Perthes disease. It affects around 1 in 1,500 children, most often boys, most often between 4 and 8 years of age. So relatively early. What happens is that for unknown reasons, the blood supply to the femoral head is suddenly disrupted. What happens is that the bone dies. And because the dead bone is then resorbed faster than new bone can be formed. The effect of that is that the femoral head collapses and deforms while the child continues to walk and put weight on the femoral head. Today, we have no disease-modifying medication to offer to these children. What is used is bracing and surgery, and it addresses only the acute symptoms. But they do not change the underlying process, and the majority are left with permanent damage to the hip; most develop debilitating osteoarthritis as adults, and around 20% will need a total hip replacement later on, or actually earlier on, because it happens sooner than it does in the normal population. So this is a disease where the mechanism is well understood, where the need is severe and where, as I said, there are no disease-modifying treatments. That is exactly the type of situation where MIV-711 can make a difference. To explain what happened and where MIV-711 comes in, and how and when to intervene in this disease, Legg-Calvé-Perthes disease progresses through four stages. Legg-Calvé-Perthes disease is caused by the blood supply loss to the femoral head. First, it is the necrosis, then fragmentation, then reossification, and finally the remodeling of the femoral head, and Cathepsin K is the key process driving this bone resorption. So by inhibiting Cathepsin K, we aim to slow the resorption and preserve the shape of the femoral head before severe fragmentation has occurred, which points us to the stage 1 to 2a that you can see on this slide, and it is consistent with the effect we have demonstrated in the disease-specific animal model that we have conducted. Good news is that these children present early. And why is that? It is because they have pain and they start limping, which brings them to medical care quickly. And the Swedish registry data shows that around 80% are diagnosed in stage 1 or 2A, so the population we can treat at diagnosis is around 60% to 80% of all patients, and that is not a small subset. With that, I will hand back to Jens.
Thank you Piya. A few strategic and commercial perspectives on this particular disease. The reason we are moving into this indication is that much of the groundwork is already in place. We have shown, as I alluded to, that in the disease-specific animal model, MIV-711 counteracts the deformity of the femoral head, which is one of the supporting elements for being granted Rare Pediatric Disease Designation. We are building on the same mechanism and the same established safety profile that we have documented in the approximately 250 subjects from our phase 1 and phase 2 osteoarthritis trials. We also have orphan drug designation and rare pediatric disease designation in place, granted by the FDA. So through the directed share issue, the phase 2 proof of concept is now funded. The next step is, however, to develop the pediatric formulation and then to move into the randomized proof of concept study and to make sure that we execute with speed, because now the program is getting bigger. We have also strengthened the organization and recruited a highly experienced clinical operations lead who will take responsibility for the operational leadership across the studies in Perthes disease and Osteogenesis Imperfecta. So importantly, it is not two separate projects. The pediatric formulation work that we do in Perthes disease will also, under those selection efforts that we will do, be highly beneficial also for the Osteogenesis Imperfecta program. So one plus one is more than two in that respect. If we then look at the commercial side of things for Legg-Calvé-Perthes disease, the primary market is around 8,800 children a year in Europe and the US. As Pia commented, we assess that around 80% of them would be suitable or accessible for treatment as an orphan drug in a pediatric population, and also being a treatment where you do not treat chronically, but rather for a year to 18 months. And we see the setting supporting a premium pricing. And then on top of that, there is of course the opportunity for rare pediatric disease and a priority review voucher. And those are currently valued at around 200 million USD if they are being sold. So taken together, we estimate annual peak sales of approximately 1 billion USD five years after marketing approval in the US and Europe, and for a program where the designations are already granted and the study is funded, we think that is a very attractive risk-reward. And stepping back and looking at MIV-711 as a whole, this is what makes the candidate special. We believe it is a third-generation, highly selective Cathepsin K inhibitor with a substantial clinical package behind it and proven radiographic benefit in phase one and phase two in osteoarthritis. So what has changed this quarter is that we now have two first-to-market opportunities from one single candidate, and neither of which has any approved treatments today. Oh, why? The market potential for Osteogenesis Imperfecta is over 2.5 billion USD, and for Perthes disease, it is approximately 1 billion USD. We have orphan drug designation in both indications. Rare Pediatric Disease Designation in Legg-Calvé-Perthes disease. And we will, of course, target Rare Pediatric Disease Designation for Osteogenesis Imperfecta as well. As I mentioned, I think that is an important element to comment on. And there are real synergies between the two programs with the development of pediatric formulation and dose selection across Perthes disease and Osteogenesis Imperfecta. So with that, I'll hand back to Pia for a further update on how the OI program is progressing.
Thank you, Jens. And just before we go into that, just a little bit of a reminder of what Osteogenesis Imperfecta is. It is also called brittle bone disease. It is a rare hereditary genetic disease. Around 1 in 15,000 births involves this disease. The mutation leads to defective or insufficient collagen production. That actually leads to these problems with the bones as well. Children are born with it, of course. They are born with it. The consequences are bones that fracture with minimal or no trauma. In the more severe forms, non-traumatic fractures can be seen. Five times or more in a year. But it is not only about the fractures. These patients live with bone and joint deformities that are often developed already in childhood. They more commonly have shorter stature and, most of all, they have chronic pain. They have significant limitations in their ability to take part in ordinary daily life. There is no approved disease-modifying treatment in OI, and with MIV-711, we are addressing the quality of the bone as well, not just the density, by reducing resorption while allowing bone formation to continue. And that is the rationale we have tested with our external experts. And it is also the rationale behind the proof of concept study in adults. I will talk about that next; we can go to the next slide. This is the study design. And I am pleased to say that the preparations are well underway. We will include approximately 20 adult patients with Osteogenesis Imperfecta who have had fractures within the previous five years. They are randomized one-to-one to two dose levels of MIV-711 and treated for 12 months. The endpoints are changes in bone biomarkers, including bone mineral density. Pharmacokinetics safety, tolerability. And we will also look at the number of fractures occurring during the treatment period and on the operational side. The interest from investigators has been really substantial and five sites are already approved. Importantly, the eligible patients are already known to these centers, as they are documented in their medical records, which is why we expect enrollment to be very fast. Preparation of clinical activities is progressing as planned, and manufacturing of study drug is on schedule. I would also highlight the commitment that we see from patient organizations, both locally and regionally in all of Europe. They help make us visible. Not invisible, but visible. It is a really good engagement that really matters for us both for recruitment and for how we design the next development step. With that, I hand back to Jens.
Thank you, Pia. I wanted to mention that there has been a lot of change over the last couple of quarters. So we want to take a bit of time to go through a bit more detail on all three programs. So with that, let's turn to the financial position and a couple of comments on the intellectual property work. And the IP positions that we are building. Clearly, one of the biggest events in the second quarter was the directed share issue in June, and we raised approximately 140 million SEK gross, or 134 million SEK net. The issue was oversubscribed, brought in two new institutional investors in Cicero Fonder and Storebrand, alongside continued strong support from Carl Bennet, Hallberg Management, LINC, and Nordea Småbolagsfond Norden. They are Nordea Småbolagsfond Norden. The effect on our cash position is substantial. We ended the quarter with 253.5 million SEK in cash, compared with 38.2 million SEK a year earlier, and we assess that our existing cash is sufficient into 2030. Most importantly, though, we now have funding in place for the three planned phase 2 studies, and this assessment does not include any proceeds from potential partnering of either Fostrox or MIV-711, nor from our existing agreements with Vetbiolix and Biossil. So is there one slide to remember from the call today? This is the one. We now have three phase 2 studies that are fully funded. Each of them carries a clear value inflection point. FLEX-HCC is the randomized 80-patient study across 12 hospitals in Korea, with the first patient dosed in May and initial recruitment progressing nicely, expected to be fully recruited within the 12-month period we have planned. Again, Legg-Calvé-Perthes disease remains without approved treatment. The funding is in place. Pediatric formulation work has been initiated ahead of the proof of concept study, and both Orphan Drug and Rare Pediatric Disease designations are already granted. So three studies, three indications without approved treatments, and the combined value potential is well beyond what our current valuation reflects. One more piece to the value story, and an important one. This, I believe, is somewhat overshadowed by all the other great pieces of news in the second quarter. This one was a bit hidden, but I wanted to stay on this because this was a big step for us and an important one. We received a notice of allowance from the US Patent and Trademark Office for the combination patent covering Fostrox plus Lenvatinib in hepatocellular carcinoma and cancer metastases to the liver. Once that patent is granted, together with the other approvals we already have in the EU, Japan, Australia, Canada, and other regions, we have protection in our key markets until at least 2041. We have protection in our key markets until at least 2041. And for a program that is now in a randomized phase 2, that length of exclusivity in the largest markets is, of course, a significant commercial asset for us. I have mentioned this before, but I wanted to stop here and highlight that for a compound like Fostrox, which is a liver-targeted compound, i.e. We will be focusing on liver cancer, having a combination patent like this, and where we also develop it in collaboration with Lenvatinib. This is in addition to our normal composition of matter patent. This is a very strong patent because these are the areas we will focus on. It will be very difficult for any generic company to challenge this particular patent or try to circumvent it after the composition of matter patent has lost its exclusivity. So this is a really strong element in strengthening the IP package we have for the compound. So with that, there are some other numbers as well. Patrik.
I will present the financial summary for Q2. As you can see, all numbers are in million SEK. The net turnover for Q2 was 1.2 million SEK, which was 300,000 lower than Q2 last year. Other external expenses were 17.9 million SEK, which was 13.4 million higher than Q1 this year, mainly due to the successful early recruitment in the FLEX-HCC study; personnel costs were 4.3 million SEK, which was 2.8 million lower than Q2 last year. The total operating costs were 22.4 million SEK, which is 2.6 million SEK lower than Q2 last year, which is mainly related to fewer employees and therefore the personnel costs are lower. The operating loss was -21.2 million SEK, which is 2 million SEK better than Q2 last year. As you can see, the cash flow from operating activities was -18.3 million SEK. We conducted the directed share issue in two tranches; 130 million SEK was received in June and 10 million SEK was received in July, totaling 140 million SEK. As Jens has said before, Medivir has a strong cash position, and the cash balance for the end of Q2 was 253.5 million. And the cash is assessed to be sufficient at least into 2030. Yes, that concludes the financial summary.
Thank you, Patrik. So bear with us. One more slide and then we will move into the Q&A session. Looking ahead at some of our most important value drivers across our programs. The priorities are, of course, clear: continued recruitment in FLEX-HCC towards full enrollment within 12 months. Clearly, we want to achieve a shorter timeline than that, but we are confident with at least 12 months; having activated the sites, the startup of the proof-of-concept study in Osteogenesis Imperfecta is the next step. And then also, of course, ensuring that we can develop a pediatric formulation as quickly as possible. So we can also start the preparations for the proof of concept study in Legg-Calvé-Perthes disease. In terms of concrete milestones, the nearest one comes from the work by our partner Vetbiolix, as they expect top-line results from the phase 2 study with MIV-711, or VBX-1000 as they call it, in periodontitis in dogs in the fourth quarter of this year. As they continue to progress the recruitment of their study in a very efficient manner, a positive outcome could generate substantial revenues for us without any material development cost of our own. Beyond that, Rare Pediatric Disease Designation in Osteogenesis Imperfecta. Completion of the feasibility work and regulatory approval of the study design in Osteogenesis Imperfecta. Top line results from FLEX-HCC in 2027 and continued strengthening of our IP across territories are also, of course, key value drivers in the coming period. So with that said, we stop. We thank everyone for listening to the presentation and we can open up for Q&A.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Hans from EVM AB. Please go ahead.
Hello. Thank you for an excellent presentation regarding the IP situation. I consider that in relation to Fostroxacitabine bralpamide monotherapy, you have a patent in China that is valid until 2035 or even further for the Fostroxacitabine bralpamide and Lenvatinib combination, which was approved globally in some important markets. You did an excellent job to get the US patent approval, but you haven't received approval yet in China. You have a pending application. What is the status and the expectations regarding that application?
Hi Hans. As you know, we never get any timelines from the patent offices. The ball is in the Chinese patent office court, and we do expect a result from them. But we could. We cannot really say when they will respond.
Can you say whether you have about the same issues that you had in the US patent process? It is about the same process. Or if it's different.
They had similar issues. But I strongly believe that we have made a good argument also in China. But as I said, we don't have a timeline for their response.
Okay. Thank you. Thank you very much. Just another question for you. The journal Lancet recently published a very interesting article regarding the future of hepatocellular carcinoma treatment. Do you have any reflections on this? That ought to be discussed since you did not mention it in your presentation.
Can you repeat what article it was in? I do not think I have. Was it about the IMbrave251 or what was it about?
No, it is an article about the future landscape of hepatocellular carcinoma treatments and how there is now a paradigm shift moving toward different combinations.
Yeah.
So if you have, will you please address the question?
No, I have actually looked into it. And I think one of the things is what you are saying, that it is combinations, and obviously there is cell therapy in this combination, but also how to use immunotherapy. But what I think is even more important is to understand the different stages when you start your systemic treatment. And there has not been any conclusion about that. And I think that the learning from our last interaction at ESMO this summer was that not all believe in using systemic treatment, regardless of which combination it might be, earlier in the disease stages, but want to use it later in the treatment sequence, which means that Fostrox plus Lenvatinib would still sort of be the right second-line therapy after an immunotherapy combination in first-line. Obviously, I am looking at all these publications with the lens of where it strategically positions Fostrox plus Lenvatinib. But that is what I took from that paper.
Okay. Thank you.
The next question comes from Richard Romanus from Redeye. Please go ahead.
Good afternoon. I have a few questions. Let's start with MIV-711 for the Legg-Calvé-Perthes disease. Could you discuss a bit more how you see the potential pricing for this disease? Considering on the one hand, it's extremely rare, which should motivate a high price. On the other hand, it is not a life-threatening disease.
No, I think that is a fair point. I think it is fair to say that we are relatively early in the development stage. So we also need to do additional pricing work to learn further. We have benchmarked this, which is an important element. Is it life-threatening? Is it severe? Is it a chronic condition? Is it something that you treat for a short period, but you still get a long-term benefit? We have benchmarked, without going into super detail, against other treatments that are similar in terms of being non-life-threatening but having similar benefits, and similar types of treatment as MIV-711, while also looking at pricing of rare diseases in general these days. And I think clearly we still see a very distinct difference between the US and Europe. But with that said, if we look at pricing today, somewhere along the lines of $150,000 to $200,000 per year in the US, and maybe not 50% in Europe, but let's say 50% to 75% of that. That would be an estimate today in terms of the pricing work that we've done. If you then look ahead a few years in terms of inflation or pricing trends. So, somewhere along the lines of 2 million SEK per year from a treatment perspective in the US, based on our estimated market potential.
And treatment during just one year.
Yes. Treatment, sorry, treatment, 12 to 18 months, depending on when the patient starts and it progresses; you will probably see some patients likely treated up to 24 months, but 12 to 18 months would be the duration for most of the patients. So I think it would probably, again, if the drug shows clinical benefit and is approved, I would be comfortable assuming an 18-month average treatment duration.
Right. That sounds reasonable. Sounds reasonable. Have you? Have you taken into consideration that MIV-711 has only been tested on adults and there may be additional risks when treating children who are growing?
So we have been looking into that, and we have actually had quite a few discussions around that. We have already investigated safety in adults, as you mentioned, in osteoarthritis. And there have been recent changes in the FDA regulation as well to make it a little bit more attractive and possible to develop. The first indication in the pediatric disease means that they have eased the requirement to, for example, start from the beginning to do a dose escalation. An allometric scaling from the dose selected in adults would potentially work, although we still need to have interactions with the regulatory authorities. This is why we are also trying to benefit from first conducting an investigation. We are conducting the study in adults to ensure we have the proof of concept. Our hypothesis of what the Cathepsin K inhibitor is doing in this population is correct. And while we are developing the pediatric formulation, because without that, we cannot proceed with any pediatric studies. We can't do a pediatric study in Legg-Calvé-Perthes disease yet. So that is what Jens talked about before, that we are having this kind of synergy or we are using another disease as well to come to the place where we actually can do the pediatric study. And I. But of course, we will have to monitor the safety very closely in the pediatric population. But there is no safety concern. You can jump in if you want to, Fredrik, but the maturity of the enzymes that are responsible for metabolizing MIV-711 is mature enough already at two years old. So we don't see that there should be any huge difference when it comes to the drug itself in the pediatric population.
And then I'll pitch in and say the following: we've done this because one of the elements is you also want to make sure that sort of the. As you treat children, the children are growing. That is a key factor. The bone develops as it should in terms of the length of the bones, and that growth continues. In the disease modeling work we have done on Perthes disease, that is also an element that we have evaluated, i.e. When they are treated with the Cathepsin K inhibitor, in this case, using a pig model, are the pigs growing as they should, not just in terms of minimizing deformity of the femoral head, but are the skeletal bones growing as they should? And it does. And so that is also an element that was important in terms of making regulators and others comfortable that, yes, it would be suitable to use a Cathepsin K inhibitor in children as well.
Yeah. And just to add that as well, though we did not mention it, many of the children have a shorter leg when they grow up because the disease impacts the femoral head, which makes it a bit shorter. So that is also important. If you can prevent the destruction of the femoral head, maybe they will not have this leg shortening after the disease.
Great answers. That is all for me. Thanks.
As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Thank you. So then before we close the call, let's come back to where we started. And this was the quarter where Fostrox was validated in a peer-reviewed journal and where the randomized FLEX-HCC study got well underway, with high engagement among the investigators and a strong start to the recruitment. It was also the quarter where MIV-711 became a two-indication program, with the funding secured for both Legg-Calvé-Perthes disease and Osteogenesis Imperfecta, where we have now finalized the study design and moved forward nicely towards starting the study. And we are building two rare disease opportunities on the same established safety profile, with an oversubscribed share issue providing 140 million SEK in cash funding for all phase two studies. We now have the financial strength to execute on all of these programs, and I would like to thank both new and existing shareholders for the confidence that makes this possible. So with that said, thank you everyone for attending and have a great rest of the day.



















